Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mifepristone |
Synonyms | |
Therapy Description |
Korlym (Mifepristone) is a progesterone receptor antagonist, which may inhibit cellular proliferation and induce apoptosis (PMID: 23180967). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mifepristone | Korlym | Corlux|Mifepriston | Hormone - Anti-progestins 6 | Korlym (Mifepristone) is a progesterone receptor antagonist, which may inhibit cellular proliferation and induce apoptosis (PMID: 23180967). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02046421 | Phase I | Mifepristone Carboplatin + Gemcitabine | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02012296 | Phase Ib/II | Mifepristone Enzalutamide | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | Completed | USA | 0 |
NCT02642939 | Phase II | Mifepristone | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |